Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Theo Wallimann (born 13 October 1946 in Alpnach, Obwalden, Switzerland) is a Swiss biologist who was research group leader and Adjunct-Professor at the Institute of Cell Biology ETH Zurich and later at the Institute of Molecular Health Science https://mhs.biol.ethz.ch/about-us/emeriti-formermembers/wallimann.html at the ETH Zurich at the Biology Department https://biol.ethz.ch/en/, of the ETH Zurich, Switzerland.
== Selected awards and honors == 2023 Christian B. Anfinsen Award 2021 American Chemical Society Nakanishi Prize 2018 Nirit and Michael Shaoul Fellow, Sackler Institute of Advanced Studies, Tel Aviv University 2016 Fellow of the International Society of Magnetic Resonance (ISMAR) 2014 Günther Laukien Prize, Experimental NMR Conference 2012 Protein Society Irving Sigal Young Investigator Award 2010 Founders Medal, International Council on Magnetic Resonance in Biological Systems 2010 Fellow of the American Association for the Advancement of Science 2003 Pure Chemistry Award, American Chemical Society 2002 Alfred P. Sloan Research Fellow, Sloan Foundation 2001 CAREER Award, National Science Foundation 1999 Beckman Young Investigator Award, Beckman Foundation
Florey was full of praise for their achievement, but disturbed that they had turned to the Americans for advice instead of him. "Am I not Australian?" he asked Keogh, "Have I not had some leading role in this thing?"
Sources: en.wikipedia.org
=== Leadership under Brian L. Halla === National Semiconductor announced the appointment of Brian L. Halla as its chairman, president and CEO on May 3, 1996. Halla was then the head of LSI logic products division. Prior to LSI, he had been with Intel for 14 years. Halla reinforced Amelio's emphasis on the expertise of National Semiconductor in analog technology. He also was, on occasions, an evangelist for analog technology. However, he found that National Semiconductor under Amelio had too few product offerings. Halla embarked on a diversification into personal computer and graphics business. He advocated PC-on-a-chip (aka system-on-a-chip) as a business direction for National Semiconductor. During his tenure at LSI, LSI had successfully applied similar concepts. However, LSI had steered clear of getting involved with PC technologies that would make it a competitor with Intel. Halla held the vision that information appliances (IAs) would succeed the personal computer as a trend. He predicted that IAs would overtake sales of PCs by the year 2000. To achieve the goal, National Semiconductor started acquiring companies that would provide the needed technological complements. Among the acquisitions were Cirrus Logic Inc's PicoPower business, for its specialised expertise in small form factor devices; Mediamatics Inc, which makes multimedia connectivity products; Future Integrated Systems Inc, a PC graphics company; Gulbransen Inc, a digital audio technology maker; ComCore Semiconductor Inc, a maker of digital signal processing for LANs; Cyrix, the maker of Intel x86 clones.
=== Azo-dyes from coupling reactions 1878 – 1885 === In 1858 Peter Griess passed ‘nitrous fumes’ (N2O3) into a solution of picramic acid (2-amino-4,6-dinitrophenol) and isolated a product belonging to a new class of compounds: azo dyes. Later, a new class of azo dyes that were based on "coupling" reactions entered the market. The new azo dyes were easy to make and assumed a vast variety of incredibly intense colors based on the chosen precursors. The chemists Z. Roussin, Heinrich Caro, O. Witt, and P. Griess all put azo dyes on the market, and attempted to keep the syntheses as industrial secrets, Hoffman, however, determined the structure of their dyes and published his findings.
=== Structure === GsMTx-4 has a polypeptide chain of 35 amino acids with the sequence GCLEF-WWKCN-PNDDK-CCRPK-LKCSK-LFKLC-NFSF, the C-terminus is amidated. The toxin is an amphipathic peptide consisting of a large hydrophobic patch which is surrounded by a ring of six polar lysine residues. These hydrophobic residues enable the toxin to carry an overall charge of +5. The toxin contains three intramolecular disulfide bonds that contribute to the formation of its inhibitor cystine knot (ICK).
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.